Open AccessInterleukin‐37 elevation in patients with atrial fibrillation
Author(s) -
Li Weidong,
Li Shijie,
Li Xianjin,
Jiang Shuzhong,
Han Bing
Publication year - 2017
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.22630
Subject(s) - medicine , pathogenesis , peripheral blood mononuclear cell , atrial fibrillation , interleukin , inflammation , immunology , c reactive protein , cytokine , in vitro , biology , biochemistry
Background Inflammation is closely related to atrial fibrillation ( AF ) pathogenesis, and interleukin‐37 ( IL ‐37) represents a new member of the anti‐inflammatory cytokines. Hypothesis IL ‐37 might play an important role in AF development and act as a potential risk factor for AF diagnosis. Methods The mRNA level of IL ‐37 in peripheral blood mononuclear cells ( PBMCs ) and serum IL ‐37 levels in AF patients and healthy controls were measured by real‐time polymerase chain reaction ( RT‐PCR ) and enzyme‐linked immunosorbent assay ( ELISA ). PBMCs from AF patients were stimulated with recombinant IL ‐37. Levels of pro‐inflammatory cytokines IL ‐6 and C‐reactive protein were determined by RT‐PCR and ELISA . Results IL ‐37 mRNAs and serum protein levels were higher in patients with AF or lone AF compared with healthy controls. Patients with paroxysmal AF or persistent AF showed higher IL ‐37 mRNAs and serum protein levels compared with those with permanent AF as well as healthy controls. In vitro, IL ‐37 inhibited the production of IL ‐6 and C‐reactive protein in PBMCs of patients with AF . Conclusions IL ‐37 is elevated in AF patients and its expression is closely associated with AF subgroups. Thus, IL ‐37 may provide a novel research target for the pathogenesis and therapy of AF . This study is the first to document elevated IL ‐37 in AF patients.